Inoviq Ltd
INOVIQ to Rework EXO-OC Study Path after Sample Quality Setback
INOVIQ retools EXO-OC path after sample quality setback; expanded retrospective data invalid, shifting to single-site/prospective validation.
Inoviq Announces Rapid Tumour-Killing Activity in Study of CAR-Exosomes on Ovarian Cancer Cells
Inoviq CAR-exosomes show rapid in vitro ovarian cancer killing, ~90% in OVCAR-3/Caov-3 within 48 hours, eyeing first-in-human trials by 2028.
INOVIQ Secures Global Rights to Novel Ovarian Cancer Biomarker Technology
INOVIQ (ASX: IIQ) has strengthened its ovarian cancer program by licensing exclusive worldwide rights to novel exosomal biomarker intellectual property from UniQuest, the commercialisation arm of The University of Queensland. The agreement gives INOVIQ the freedom to develop and commercialise the biomarkers as part of its EXO-OC test, a blood test for the early detection and […]
INOVIQ reports 88% kill rate of breast and lung cancer cells in CAR-exosome therapy study
INOVIQ (ASX: IIQ) has reported superior efficacy from an in vitro study of CAR-exosomes cancer therapy that killed almost 88% of triple-negative breast cancer (TNBC) and lung cancer cells within 96 hours. Real-time cell analysis demonstrated that CAR-NK-EVs — chimeric antigen receptor natural killer cells derived from extracellular vesicles — exerted a significant cytotoxic effect […]